About Alivus Life Sciences Limited
Data last updated: 09 January 2026
Alivus Life Sciences Limited is a public limited company based in Solapur, Maharashtra, India, a subsidiary of Nirma Limited. It specialises in api manufacturers, a part of the broader pharmaceuticals sector. Incorporated on 23 June 2011, the company has been in operation for over 15 years.
Registered with ROC Pune under CIN L74900PN2011PLC139963. Listed on BSE: 543322 and NSE: GLS.
Capital: an authorised share capital of ₹46 Cr and a paid-up capital of ₹24.54 Cr. Formerly known as Zorg Laboratories Private Limited and Glenmark Life Sciences Private Limited. It is led by directors including Yasir Yusufali Rawjee and Manju Agarwal.
Last AGM: 08 September 2025. Financial statements filed for year ended 31 March 2025. Office: Solapur, Maharashtra.
As per the financials filed for FY 2025, the company reported a revenue of ₹2,421.45 Cr, a growth of 5% compared to the previous year.
The company has a workforce of approximately 2,021 employees as per the latest available data. It operates as a subsidiary of Nirma Limited.
The company is associated with 2 brands - Glenmark Life Sciences, Alivus.
The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website glenmarklifesciences.com.
-
Email*****@*****.com
-
Telephone+91-****-******
-
Website
-
Social Media
-
Registered AddressPlot No 170 – 172 Chandramouli Industrial Estate Mohol Ba, Zarpeth, Solapur, Maharashtra, India – 413213
-
IndustryPharma, API Manufacturers
- Historical Financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Litigation, compliance and MCA filings
- PDF report delivered after checkout
Name History of Alivus Life Sciences Limited
Alivus Life Sciences Limited has undergone 2 name changes throughout its history. The company was previously known as Zorg Laboratories Private Limited, and Glenmark Life Sciences Private Limited. The current legal name is Alivus Life Sciences Limited, reflecting the company's evolution and rebranding over time.
| Company Name | Status |
|---|---|
| Alivus Life Sciences Limited | Current |
| Zorg Laboratories Private Limited | Previous |
| Glenmark Life Sciences Private Limited | Previous |
CIN History of Alivus Life Sciences Limited
Alivus Life Sciences Limited has 2 previous CINs, indicating changes in the company's corporate structure or registration details. The current CIN is L74900PN2011PLC139963, which is the unique identifier assigned by the Registrar of Companies.
| CIN | Status |
|---|---|
| L74900PN2011PLC139963 | Current |
| U74900PN2011PTC139963 | Previous |
| U74900PN2011PLC139963 | Previous |
Associated Brands with Alivus Life Sciences Limited
Alivus Life Sciences Limited operates two associated brands: Glenmark Life Sciences and Alivus. These brands represent Alivus Life Sciences Limited's diversified market presence and brand portfolio.
| Brand | Description | Website |
|---|---|---|
| API manufacturing is provided by the CDMO in India. | glenmarklifesciences.com | |
| High-value APIs are developed and manufactured for global partners. | alivus.com |
Competitors & Alternatives of Alivus Life Sciences Limited
Brands and companies operating in the same space as Alivus Life Sciences Limited include Laurus Labs, Symbiotec, Beijing Biostar Technologies and 6 more.
| Competitor | Description | Location | Founded |
|---|---|---|---|
Laurus Labs
|
Pharmaceutical and biotechnology company | Hyderabad, India, India | 2005 |
Symbiotec
|
Non-sterile steroid hormone-based APIs and intermediates are manufactured. | Indore, India, India | 2002 |
Beijing Biostar Technologies
|
APIs, intermediates, and biochemical reagents are developed and manufactured. | Beijing, China, China | 2002 |
Sterling Pharma Solutions
|
Contract development, manufacturing, and analytical services for APIs are offered. | Dudley, United Kingdom, United Kingdom | 2016 |
Provepharm Life Solutions
|
APIs and drug products are developed and valorized in pharmaceuticals. | Marseille, France, France | 1998 |
Hikal
|
APIs and intermediates are produced via custom synthesis and research. | Mumbai, India, India | 1988 |
Snapdragon Chemistry
|
Drug discovery and development service provider | Cambridge, United States, United States | 2014 |
SeQuent
|
APIs are developed and manufactured for therapeutic areas. | Bengaluru, India, India | 2002 |
Jubilant Pharma
|
Pharmaceuticals, APIs, and radiopharmaceuticals are manufactured by the company. | Noida, India, India | 1978 |
Business Activity of Alivus Life Sciences Limited
Alivus Life Sciences Limited is engaged in the principal business activity of manufacturing, with detailed activities including chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products.
| Main Activity Group Code | Description of Main Activity | Business Activity Code | Description of Business Activity | Turnover Percentage |
|---|---|---|---|---|
| C | Manufacturing | C6 | Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products | ********* |
Auditor Details of Alivus Life Sciences Limited
Alivus Life Sciences Limited is audited by Walker Chandiok & Co LLP (ICAI peer reviewed, certificate valid till 2028-05-31) for the financial year 2026, as reported in its NSE exchange filings. The statutory auditor is responsible for expressing an independent opinion on whether the financial statements present a true and fair view in accordance with applicable accounting standards.
| Name | Financial year | Audit opinion |
|---|---|---|
| Walker Chandiok & Co LLP (ICAI peer reviewed, certificate valid till 2028-05-31) | FY 2026 | Declaration of unmodified opinion |
Board of Directors of Alivus Life Sciences Limited
Alivus Life Sciences Limited is currently managed by 9 directors, with 19 former directors having served the organization. The current Directors play a crucial role in shaping the company's strategic direction and governance.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Yasir Yusufali Rawjee | Managing Director | 26 Sep 2019 | 6 Years 9 Months | Current |
|
Manju Agarwal
Also directs:
Gulf Oil Lubricants India Limited, Gocl Corporation Limited, Polycab India Limited and 5 more
|
Director | 08 Mar 2021 | 5 Years 4 Months | Current |
| Vinod Naik | Whole-Time Director | 21 Oct 2022 | 3 Years 8 Months | Current |
|
Kaushikbhai Nandubhai Patel
Also directs:
Nuvoco Vistas Corporation Limited, Nirma Limited
|
Director | 06 Mar 2024 | 2 Years 4 Months | Current |
| Hiren Karsanbhai Patel | Director | 06 Mar 2024 | 2 Years 4 Months | Current |
|
Tushar Pravinchandra Mistry
Also directs:
Tunika Ventures Llp
|
Cfo | 01 Jun 2022 | 4 Years 1 Months | Current |
Financials of Alivus Life Sciences Limited FY 2026 filings available
Alivus Life Sciences Limited reported revenue of ₹2,551.83 Cr (up 6.91% YoY) for FY 2026. Profit growth despite declining revenue indicates effective cost management and margin discipline.
| Metrics | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
| Revenue from Operations | ₹2,551.83 Cr | ₹2,386.88 Cr | ₹2,283.21 Cr | ₹2,161.22 Cr | ₹2,123.21 Cr |
| Other Income | ₹60.41 Cr | ₹34.57 Cr | ₹12.04 Cr | ₹28.96 Cr | ₹14.7 Cr |
| Total Income | ₹2,612.24 Cr | ₹2,421.45 Cr | ₹2,295.26 Cr | ₹2,190.18 Cr | ₹2,137.92 Cr |
| Cost of Materials Consumed | ₹1,063.01 Cr | ₹1,053.5 Cr | ₹1,058.58 Cr | ₹1,098.53 Cr | ₹1,001.56 Cr |
| Purchases of Stock-in-Trade | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| Changes in Inventories | ₹3.56 Cr | ₹27.35 Cr | -₹56.57 Cr | -₹84.44 Cr | ₹41.32 Cr |
| Employee Benefit Expense | ₹272.47 Cr | ₹251.7 Cr | ₹258.16 Cr | ₹180.18 Cr | ₹168.72 Cr |
| Finance Costs | ₹5.37 Cr | ₹2.41 Cr | ₹1.55 Cr | ₹54.7 Lakh | ₹27.96 Cr |
| Depreciation & Amortisation | ₹75.36 Cr | ₹60.61 Cr | ₹53.45 Cr | ₹42.09 Cr | ₹37.88 Cr |
| Other Expenses | ₹415.51 Cr | ₹371.75 Cr | ₹348.8 Cr | ₹324.66 Cr | ₹295.54 Cr |
| Total Expenses | ₹1,835.28 Cr | ₹1,767.32 Cr | ₹1,663.97 Cr | ₹1,561.57 Cr | ₹1,572.99 Cr |
| Profit Before Exceptional Items & Tax | ₹776.97 Cr | ₹654.13 Cr | ₹631.29 Cr | ₹628.61 Cr | ₹564.93 Cr |
| Exceptional Items | -₹25.66 Cr | ₹0 | ₹0 | ₹0 | ₹0 |
| Profit Before Tax | ₹751.31 Cr | ₹654.13 Cr | ₹631.29 Cr | ₹628.61 Cr | ₹564.93 Cr |
| Total Tax Expense | ₹186.83 Cr | ₹168.5 Cr | ₹160.4 Cr | ₹161.65 Cr | ₹146.2 Cr |
| Net Profit | ₹564.48 Cr | ₹485.63 Cr | ₹470.89 Cr | ₹466.96 Cr | ₹418.72 Cr |
| Other Comprehensive Income | ₹1.22 Cr | -₹1.25 Cr | -₹5.46 Cr | -₹29 Lakh | ₹9.7 Lakh |
| Total Comprehensive Income | ₹565.71 Cr | ₹484.38 Cr | ₹465.43 Cr | ₹466.67 Cr | ₹418.82 Cr |
| EBITDA (computed) | ₹857.7 Cr | ₹717.15 Cr | ₹686.29 Cr | ₹671.25 Cr | ₹630.76 Cr |
| Basic EPS | ₹45.99 | ₹39.63 | ₹38.43 | ₹38.11 | ₹35.63 |
| Diluted EPS | ₹45.90 | ₹39.52 | ₹38.38 | ₹38.11 | ₹35.63 |
| Metrics | FY 2026 | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|---|
| Total Assets | ₹3,982.9 Cr | ₹3,411.45 Cr | ₹2,850.41 Cr | ₹2,702.15 Cr |
| Non-current Assets | ₹1,333.54 Cr | ₹1,076.3 Cr | ₹934.41 Cr | ₹851.81 Cr |
| Current Assets | ₹2,649.36 Cr | ₹2,335.16 Cr | ₹1,916 Cr | ₹1,850.34 Cr |
| Property, Plant & Equipment | ₹1,017.97 Cr | ₹942.67 Cr | ₹795.01 Cr | ₹774.89 Cr |
| Inventories | ₹691.93 Cr | ₹673.95 Cr | ₹666.59 Cr | ₹604.17 Cr |
| Trade Receivables | ₹1,072.96 Cr | ₹969.74 Cr | ₹765.43 Cr | ₹806.77 Cr |
| Cash & Equivalents | ₹1.98 Cr | ₹71.06 Cr | ₹301.41 Cr | ₹283.82 Cr |
| Equity (Net Worth) | ₹3,332.13 Cr | ₹2,817.37 Cr | ₹2,332.32 Cr | ₹2,138.21 Cr |
| Equity Share Capital | ₹24.55 Cr | ₹24.51 Cr | ₹24.51 Cr | ₹24.51 Cr |
| Borrowings (Non-current) | ₹0 | ₹0 | ₹0 | ₹0 |
| Borrowings (Current) | ₹0 | ₹0 | ₹0 | ₹0 |
| Total Debt (computed) | ₹0 | ₹0 | ₹0 | ₹0 |
| Current Liabilities | ₹508.04 Cr | ₹470.16 Cr | ₹438.77 Cr | ₹504.41 Cr |
| Total Liabilities | ₹650.77 Cr | ₹594.08 Cr | ₹518.09 Cr | ₹563.94 Cr |
| Metrics | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
| Operating Cash Flow | ₹565.41 Cr | ₹391.52 Cr | ₹413.52 Cr | ₹313.4 Cr | ₹597.59 Cr |
| Investing Cash Flow | -₹570.15 Cr | -₹615.65 Cr | -₹116.48 Cr | -₹154.15 Cr | -₹122.23 Cr |
| Financing Cash Flow | -₹64.34 Cr | -₹6.23 Cr | -₹279.44 Cr | -₹387.59 Cr | -₹78.8 Cr |
| Capital Expenditure | ₹307.06 Cr | ₹166.19 Cr | ₹128.97 Cr | ₹170.2 Cr | ₹132.17 Cr |
| Free Cash Flow (computed) | ₹258.36 Cr | ₹225.34 Cr | ₹284.55 Cr | ₹143.21 Cr | ₹465.41 Cr |
| Dividends Paid | ₹61.34 Cr | ₹0 | ₹275.69 Cr | ₹385.92 Cr | ₹128.65 Cr |
| Net Change in Cash | -₹69.08 Cr | -₹230.35 Cr | ₹17.59 Cr | -₹228.33 Cr | ₹396.56 Cr |
| Metrics | Q4 FY26 | Q3 FY26 | Q2 FY26 | Q1 FY26 | Q4 FY25 | Q3 FY25 | Q2 FY25 | Q1 FY25 | Q4 FY24 | Q3 FY24 | Q2 FY24 | Q1 FY24 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue from Operations | ₹689.12 Cr | ₹672.89 Cr | ₹587.98 Cr | ₹601.85 Cr | ₹649.55 Cr | ₹641.84 Cr | ₹506.88 Cr | ₹588.62 Cr | ₹536.6 Cr | ₹572.8 Cr | ₹595.36 Cr | ₹578.45 Cr |
| Other Income | ₹22.78 Cr | ₹13.93 Cr | ₹14.72 Cr | ₹8.99 Cr | ₹10.09 Cr | ₹10.46 Cr | ₹8.53 Cr | ₹5.49 Cr | ₹3.13 Cr | ₹1.69 Cr | ₹5.37 Cr | ₹1.85 Cr |
| Total Income | ₹711.9 Cr | ₹686.82 Cr | ₹602.7 Cr | ₹610.83 Cr | ₹659.63 Cr | ₹652.3 Cr | ₹515.41 Cr | ₹594.11 Cr | ₹539.73 Cr | ₹574.5 Cr | ₹600.73 Cr | ₹580.3 Cr |
| Cost of Materials Consumed | ₹228.71 Cr | ₹276.36 Cr | ₹288.96 Cr | ₹268.98 Cr | ₹280.45 Cr | ₹287.62 Cr | ₹239.08 Cr | ₹246.36 Cr | ₹247.84 Cr | ₹243.13 Cr | ₹269.4 Cr | ₹298.21 Cr |
| Purchases of Stock-in-Trade | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| Changes in Inventories | ₹42.14 Cr | ₹5.6 Lakh | -₹40.04 Cr | ₹1.41 Cr | ₹2.14 Cr | -₹2.35 Cr | -₹13.88 Cr | ₹41.43 Cr | -₹9.14 Cr | -₹93.3 Lakh | ₹3.68 Cr | -₹50.17 Cr |
| Employee Benefit Expense | ₹78.12 Cr | ₹66.37 Cr | ₹66.4 Cr | ₹61.58 Cr | ₹66.72 Cr | ₹65.69 Cr | ₹62.44 Cr | ₹56.84 Cr | ₹72.26 Cr | ₹71.05 Cr | ₹66.71 Cr | ₹48.13 Cr |
| Finance Costs | ₹1.31 Cr | ₹1.49 Cr | ₹1.32 Cr | ₹1.25 Cr | ₹1.26 Cr | ₹45.8 Lakh | ₹34.3 Lakh | ₹35.3 Lakh | ₹36.4 Lakh | ₹38.7 Lakh | ₹39.9 Lakh | ₹39.6 Lakh |
| Depreciation & Amortisation | ₹20.2 Cr | ₹19.66 Cr | ₹18.44 Cr | ₹17.06 Cr | ₹15.97 Cr | ₹15.16 Cr | ₹15.09 Cr | ₹14.39 Cr | ₹14.53 Cr | ₹13.18 Cr | ₹13.13 Cr | ₹12.61 Cr |
| Other Expenses | ₹125.62 Cr | ₹98.83 Cr | ₹93.49 Cr | ₹97.57 Cr | ₹101.8 Cr | ₹100.57 Cr | ₹84.89 Cr | ₹84.5 Cr | ₹84.2 Cr | ₹87 Cr | ₹88.49 Cr | ₹89.12 Cr |
| Total Expenses | ₹496.1 Cr | ₹462.77 Cr | ₹428.56 Cr | ₹447.85 Cr | ₹468.34 Cr | ₹467.15 Cr | ₹387.96 Cr | ₹443.87 Cr | ₹410.05 Cr | ₹413.81 Cr | ₹441.81 Cr | ₹398.3 Cr |
| Profit Before Exceptional Items & Tax | ₹215.8 Cr | ₹224.05 Cr | ₹174.14 Cr | ₹162.98 Cr | ₹191.29 Cr | ₹185.15 Cr | ₹127.46 Cr | ₹150.24 Cr | ₹129.68 Cr | ₹160.68 Cr | ₹158.93 Cr | ₹182 Cr |
| Exceptional Items | ₹0 | -₹25.66 Cr | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| Profit Before Tax | ₹215.8 Cr | ₹198.39 Cr | ₹174.14 Cr | ₹162.98 Cr | ₹191.29 Cr | ₹185.15 Cr | ₹127.46 Cr | ₹150.24 Cr | ₹129.68 Cr | ₹160.68 Cr | ₹158.93 Cr | ₹182 Cr |
| Total Tax Expense | ₹53.14 Cr | ₹48.13 Cr | ₹44.11 Cr | ₹41.45 Cr | ₹49.42 Cr | ₹48.19 Cr | ₹32.14 Cr | ₹38.76 Cr | ₹31.74 Cr | ₹41.92 Cr | ₹40.19 Cr | ₹46.55 Cr |
| Net Profit | ₹162.66 Cr | ₹150.26 Cr | ₹130.03 Cr | ₹121.54 Cr | ₹141.87 Cr | ₹136.96 Cr | ₹95.32 Cr | ₹111.48 Cr | ₹97.94 Cr | ₹118.77 Cr | ₹118.74 Cr | ₹135.45 Cr |
| Other Comprehensive Income | ₹1.28 Cr | -₹4.2 Lakh | ₹28.8 Lakh | -₹30.4 Lakh | -₹15.1 Lakh | -₹38.6 Lakh | -₹53.7 Lakh | -₹17.4 Lakh | ₹14.2 Lakh | -₹3.54 Cr | -₹1.99 Cr | -₹7.3 Lakh |
| Total Comprehensive Income | ₹163.94 Cr | ₹150.22 Cr | ₹130.31 Cr | ₹121.23 Cr | ₹141.72 Cr | ₹136.57 Cr | ₹94.78 Cr | ₹111.31 Cr | ₹98.08 Cr | ₹115.22 Cr | ₹116.75 Cr | ₹135.38 Cr |
| EBITDA (computed) | ₹237.31 Cr | ₹245.2 Cr | ₹193.89 Cr | ₹181.3 Cr | ₹208.52 Cr | ₹200.76 Cr | ₹142.89 Cr | ₹164.98 Cr | ₹144.58 Cr | ₹174.25 Cr | ₹172.45 Cr | ₹195.01 Cr |
| Basic EPS | ₹13.23 | ₹12.25 | ₹10.60 | ₹9.91 | ₹11.57 | ₹11.18 | ₹7.78 | ₹9.10 | ₹7.99 | ₹9.69 | ₹9.69 | ₹11.05 |
| Diluted EPS | ₹13.22 | ₹12.22 | ₹10.58 | ₹9.88 | ₹11.55 | ₹11.14 | ₹7.75 | ₹9.08 | ₹7.97 | ₹9.67 | ₹9.69 | ₹11.05 |
Shareholding Pattern of Alivus Life Sciences Limited
As per the shareholding pattern filed with NSE for the quarter ended Mar 2026, promoters hold 74.87%, foreign institutional investors hold 5.29%, domestic institutional investors hold 7.28%, retail and other public shareholders hold 12.56% of Alivus Life Sciences Limited. The company had 127,969 shareholders on record.
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | |
|---|---|---|---|---|---|---|
| Promoters | 74.87% | 74.91% | 74.91% | 74.94% | 74.99% | 75.00% |
| Public | 25.13% | 25.09% | 25.09% | 25.06% | 25.01% | 25.00% |
| Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | |
|---|---|---|---|---|---|
| Promoters | 74.87% | 74.99% | 82.85% | 82.85% | 82.85% |
| Public | 25.13% | 25.01% | 17.15% | 17.15% | 17.15% |
| Promoter change (YoY, %pts) | -0.12 | -7.86 | +0.00 | +0.00 | - |
Board & Governance of Alivus Life Sciences Limited
As per the corporate governance filing with NSE for the quarter ended 31-MAR-2026, the board of Alivus Life Sciences Limited has 7 directors - 4 independent and 2 executive. The board is chaired by Hiren Karsanbhai Patel.
| Director | Position | On board since | Listed boards |
|---|---|---|---|
| Hiren Karsanbhai Patel | Non-Executive - Non Independent Director · Chairperson | 2024-03-06 | 2 |
| Yasir Yusufali Rawjee | Executive Director · CEO-MD | 2019-08-13 | 1 |
| Vinod Naik | Executive Director | 2022-10-21 | 1 |
| Kaushikbhai N. Patel | Non-Executive - Independent Director | 2024-03-06 | 2 |
| Manju Agarwal | Non-Executive - Independent Director | 2020-10-30 | 4 |
| Taruvai Laxminarayanan Easwar | Non-Executive - Independent Director | 2021-01-08 | 1 |
| Savan Godiawala | Non-Executive - Independent Director | 2024-04-25 | 3 |
| Committee | Members |
|---|---|
| Audit Committee | Kaushikbhai N. Patel (Chairperson), Manju Agarwal, Taruvai Laxminarayanan Easwar, Savan Godiawala |
| Nomination and remuneration committee | Kaushikbhai N. Patel (Chairperson), Hiren Karsanbhai Patel, Manju Agarwal, Savan Godiawala |
| Stakeholders Relationship Committee | Taruvai Laxminarayanan Easwar (Chairperson), Yasir Yusufali Rawjee, Manju Agarwal |
| Risk Management Committee | Kaushikbhai N. Patel (Chairperson), Yasir Yusufali Rawjee, Taruvai Laxminarayanan Easwar |
| Corporate Social Responsibility Committee | Kaushikbhai N. Patel (Chairperson), Yasir Yusufali Rawjee, Savan Godiawala |
Charges & Borrowings Alivus Life Sciences Limited
Alivus Life Sciences Limited does not have any charges (loans) registered with the Registrar of Companies.
Employees and EPFO Compliance at Alivus Life Sciences Limited
Alivus Life Sciences Limited has a workforce of 2,021 employees as of Feb 28, 2025.
Employee Count & EPFO Data of Alivus Life Sciences Limited
Access employee headcount trends, monthly PF payment records, EPFO establishment details, and compliance data.
GST Compliance of Alivus Life Sciences Limited
GSTIN & GST Filing Data of Alivus Life Sciences Limited
Access GSTIN registrations, state-wise filing compliance, HSN/SAC codes, and detailed goods & services data.
Credit Ratings, Litigation & Regulatory Alerts for Alivus Life Sciences Limited
Credit Ratings, Legal Cases & Regulatory Alerts of Alivus Life Sciences Limited
Access complete credit rating history, litigation records, regulatory alerts, and compliance data.
MSME Payment Delays by Alivus Life Sciences Limited
MSME Payment Delays by Alivus Life Sciences Limited
Track payments outstanding to micro and small enterprise vendors, as disclosed in half-yearly MSME-1 returns filed with the MCA.
Subsidiaries & Group Companies of Alivus Life Sciences Limited
Subsidiaries & Group Companies of Alivus Life Sciences Limited
See the full corporate group - holding company, subsidiaries, associates and joint ventures of Alivus Life Sciences Limited with ownership details.
MCA Filings & Documents of Alivus Life Sciences Limited
MCA Filings & Documents of Alivus Life Sciences Limited
Download official documents filed with the Ministry of Corporate Affairs - from incorporation papers to the latest annual filings.
Recent Activity on Alivus Life Sciences Limited
Recent News on Alivus Life Sciences Limited
Frequently Asked Questions about Alivus Life Sciences Limited
Alivus Life Sciences Limited is an active public limited company in the pharma sector based in Solapur, Maharashtra, India. It was incorporated on 23 June 2011 (15+ years old) and is registered under CIN L74900PN2011PLC139963. Listed on BSE: 543322 and NSE: GLS. The company has 2,021 employees.
Alivus Life Sciences Limited reported revenue of ₹2,421.45 Cr for FY 2025 (up 5.00% YoY).
The current directors of Alivus Life Sciences Limited are:
The primary industry of Alivus Life Sciences Limited is pharma. The company specifically operates in api manufacturers. The company is currently active in this sector.
Yes. Alivus Life Sciences Limited is listed on both BSE (code: 543322) and NSE (symbol: GLS).
Alivus Life Sciences Limited can be reached at the registered office: Plot No 170 – 172 Chandramouli Industrial Estate Mohol Ba, Zarpeth, Solapur, Maharashtra, India – 413213, or through the website glenmarklifesciences.com.